#United States #Birmingham #RxBenefits #Pharmacy Benefits #PBM Evaluation

Evaluating Pharmacy Benefits Managers: Insights from RxBenefits

RxBenefits, Inc., recognized as the nation's sole pharmacy benefits optimizer, has unveiled a comprehensive Market Report titled "How to Evaluate Transparent PBMs with Confidence: A Practical Guide for Benefits Advisors." Released on August 10, 2026, the report intends to empower benefits advisors and HR leaders by offering a structured approach to assess pharmacy benefits managers (PBMs). As evolving federal and state transparency legislation continues to reshape the landscape of self-funded employers, understanding PBM dynamics becomes increasingly vital.

Key Findings: Transparency vs. Savings

The report presents a crucial finding that challenges a prevalent notion in the industry: while transparency is critical, it does not automatically translate into cost savings. The introduction of pass-through contracts has enhanced visibility into plan-related finances, but it is only one part of the equation. The distinction between successful and underperforming vendors primarily lies in their operational execution, effective utilization management strategies, and their commitment to maintaining high service quality post-implementation.

Five Evaluation Areas

One of the report's highlights is the delineation of five essential areas for benefits advisors to scrutinize when evaluating PBM vendors:
1. Savings Execution
2. Clinical Depth
3. Channel Optimization
4. Implementation Quality
5. Service Durability

Among these categories, clinical management depth stands out as the most critical differentiator for advisors when selecting the right PBM partner. Personalized clinical reviews focused on high-cost prescriptions tend to yield superior outcomes compared to automated systems reliant solely on predetermined criteria. Intriguingly, fewer than 2% of prescription claims account for over half of the total pharmacy expenditures. Hence, the implication of strategically managing these claims is paramount for overall cost control.

The Rising Costs of Specialty Drugs

The report provides context for the escalating costs associated with specialty medications, noting that a single specialty drug can exorbitantly inflate plan costs by over $250,000 annually. A glaring example of this trend can be observed with GLP-1 medications, whose national spending surged by more than 500% from 2018 to 2023. Such statistics underline the urgent need for effective PBM strategies that can manage these financial pressures and enhance patient care.

Insights from RxBenefits Leadership

Nathan White, Chief Client Officer at RxBenefits, emphasizes the evolving definition of transparency in the PBM sector, asserting that “Transparency is the price of entry now, not the finish line.” He argues that advisors who can consistently reduce net costs must look beyond pricing structures to elements such as clinical depth and active channel engagement, as these factors are where the real savings materialize.

Upcoming Webinar for Benefits Advisors

To expand on the insights highlighted in the report, RxBenefits will host a webinar titled “The Transparent PBM Shift: What It Means for Your Clients” on Tuesday, August 11, at 11 a.m. CT/12 p.m. ET. The event will facilitate a moderated panel featuring Nathan White and Mark Campbell, PharmD, Chief Pharmacy Officer at RxBenefits, specifically tailored for benefits advisors representing self-insured plans. Registration details can be found on their website.

Conclusion

The launch of RxBenefits’ Market Report marks a significant step toward assisting benefits advisors in navigating the complexities of pharmacy benefits management. By focusing on crucial evaluation areas and promoting a deeper understanding of transparent PBM strategies, RxBenefits seeks to enhance both cost-effective solutions and optimal care quality for members nationwide. For more details or to access the full report, visit RxBenefits.